C4 Therapeutics (CCCC) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
C4 Therapeutics is the larger company by market cap ($346.9 million vs $295.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CCCC | SRZN |
|---|---|---|
| Share price | $2.82 | $25.15 |
| Market cap | $346.93M | $295.54M |
| 1-day change | -2.08% | -4.65% |
| YTD return | +47.64% | — |
| 1-year return | +24.78% | — |
| 5-year return | -93.57% | — |
| EPS (TTM) | $-0.91 | $-37.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $37.83 |
| 52-week low | $1.69 | $11.39 |
| Distance from 52-week high | -45.45% | -33.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +372.70% | +92.48% |
| Average volume | 2.39M | 471.01K |
| Shares outstanding | 123.03M | 11.75M |
| Employees | 104 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Healthcare · Biotechnology · 44 employees
CCCC vs SRZN FAQ
Which is bigger, C4 Therapeutics or Surrozen?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $346.93M compared with $295.54M for Surrozen (SRZN).
Are C4 Therapeutics and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.